Shanghai, China · Founded 2018 · Privately Held (backing)
Developer of personalized dendritic cell tumor vaccines intended to provide new treatment approaches and strategies for relapsed and refractory tumors. Hengsai Bio is based in Shanghai, China and was founded in 2018. It has raised $18.6 million.
Last price · $/share
—
Implied valuation
—
Total raised
$18.6M
Last round
—
Cap table — not yet on record
Hengsai Bio's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Hengsai Bio with a free account
·Watch Hengsai Bio: the Monday email on marks, rounds and moves
